# EDGAR Filing Document

**Accession Number:** 0001505497
**File Stem:** 0001021771-25-000131
**Filing Date:** 2025-9
**Character Count:** 6360
**Document Hash:** 4bbda761b117bbee16d12242074e1fe1
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001021771-25-000131.hdr.sgml**: 20250925

**ACCESSION NUMBER**: 0001021771-25-000131

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20250918

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20250925

**DATE AS OF CHANGE**: 20250925

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BioRestorative Therapies, Inc.
- **CENTRAL INDEX KEY:** 0001505497
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 301341024
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37603
- **FILM NUMBER:** 251341309

**BUSINESS ADDRESS:**
- **STREET 1:** 40 MARCUS DRIVE
- **CITY:** MELVILLE
- **STATE:** NY
- **ZIP:** 11747
- **BUSINESS PHONE:** (631) 760-8100

**MAIL ADDRESS:**
- **STREET 1:** 40 MARCUS DRIVE
- **CITY:** MELVILLE
- **STATE:** NY
- **ZIP:** 11747

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Stem Cell Assurance, Inc.
- **DATE OF NAME CHANGE:** 20101110

?xml version='1.0' encoding='ASCII'?

------

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

### FORM 8-K

#### CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

#### Date of Report (Date of earliest event reported): September 18, 2025

## BioRestorative Therapies, Inc.
(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Nevada**<br>| **001-37603**<br>| **30-1341024**<br>|
| (State or other jurisdiction <br> of incorporation) | (Commission <br> File Number) | (IRS Employer <br> Identification No.) |

---

---

| | |
|:---|:---|
| **40 Marcus Drive<br> Melville, New York**  | **11747<br>**  |
| (Address of principal executive offices) | (Zip code) |

---

Registrant's telephone number, including area code (631) 760-8100

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

<u>Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:</u>

---

| | | |
|:---|:---|:---|
| <u>Title of each class</u> | <u>Trading Symbol(s)</u> | <u>Name of each exchange on which registered</u> |
| Common Stock, $0.0001 par value | BRTX | NASDAQ Capital Market |

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter):

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 5.07 Submission of Matters to a Vote of Security Holders**

On September 18, 2025, BioRestorative Therapies, Inc. (the "Company") held its Annual Meeting of Stockholders (the "Annual Meeting"). At the Annual Meeting, the Company's stockholders: (i) elected the nominees as the Class II directors, (ii) approved an amendment to the Company's 2021 Stock Incentive Plan (the "Plan") to increase the number of shares of common stock authorized to be issued pursuant to the Plan from 6,850,000 to 9,850,000, (iii) ratified the selection of CBIZ CPAs P.C. as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025, and (iv) approved, on a non-binding advisory basis, the compensation of the Company's executive officers.

The following is a listing of the votes cast for or withheld, and the number of broker non-votes, with respect to the nominees for Class II directors and a listing of the votes cast for and against, as well as abstentions and broker non-votes, with respect to the other matters voted upon at the Annual Meeting, as applicable.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. Election of Class II Directors:

---

| | | | |
|:---|:---|:---|:---|
|  | Number of Shares | Number of Shares | Number of Shares |
|  | For | Withheld | Broker Non-Votes |
| &nbsp;&nbsp;&nbsp; Francisco Silva | 1,591,913 | &nbsp;&nbsp;&nbsp;&nbsp;73,999 | 3,328,582 |
| &nbsp;&nbsp;&nbsp; David Rosa | 1,473,937 | 191,975 | 3,328,582 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. Approval of amendment to the Company's 2021 Stock Incentive Plan:

---

| | |
|:---|:---|
| For | 1,340,653 |
| Against | 289,308 |
| Abstentions | 35,951 |
| Broker Non-Votes | 3,328,582 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. Ratification of the selection of CBIZ CPAs P.C. as the Company's independent registered public accounting firm for the fiscal year ending December 31,
 2025:

<u> For </u> <u> 4,718,630 </u> <br> <u> Against </u> <u> 271,000 </u> <br> <u> Abstentions </u> <u> 4,864 </u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. Approval, on a non-binding advisory basis, of the compensation of the Company's executive officers:

---

| | |
|:---|:---|
| For | 1,539,396 |
| Against | 106,661 |
| Abstentions | 19,855 |
| Broker Non-Votes | 3,328,582 |

---

------

#### SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **BIORESTORATIVE THERAPIES, INC.** | **BIORESTORATIVE THERAPIES, INC.** |
| Dated: September 25, 2025<br>| By:  | /s/ Robert Kristal |
|  |  | Robert Kristal |
|  |  | Chief Financial Officer |

---